In a few days, the $3 billion California stem cell agency is slated to pick a new president who will oversee what could be the last years of its life.
The governing board of the California Institute of Regenerative Medicine (CIRM), as the agency is formally known, is scheduled to make the decision Wednesday on the new CEO and his or her pay, which may top $500,000 annually and predictably stir public outrage.
It is a watershed moment for the nearly 10-year-old agency. Not only does it need a new president, it needs more cash, along with results that will resonate widely with the public and potential funding sources. Money for new research awards is scheduled to run out in 2017. To help build support and attract cash, CIRM has begun an aggressive push to commercialize stem cell research. The hope is to fulfill the promises of cures that were made during the ballot initiative campaign that created the program in 2004.
Overall, the agency, which has 56 employees, has handed out about $1.7 billion since it was created by California voters when they approved Proposition 71. The measure funded the agency directly from state borrowing (bonds), with no intervention by the governor or Legislature. No cures have yet resulted from CIRMs spending.
The agencys new chief will replace scientist Alan Trounson, who said last fall that he was resigning to rejoin his family in Australia. Trounson was hired in 2008 at an annual salary of $490,008, where it remains today.
Late last year, the agency pointedly specified that the new CEO did not have to be a scientist. Hiring someone from the private sector, however, could mean offering a salary higher than Trounsons.
The new president and the agency face other issues, particularly developing what the agency calls a sustainability plan that would finance it beyond 2017. CIRM Chairman Jonathan Thomas is examining the possibility of a public-private partnership and is pitching the agencys achievements to possible funding sources.
Asked last week to summarize CIRMs accomplishments, Thomas said in an email, In just a few short years we didnt start funding research in earnest until 2007 we have helped make California the world leader in stem cell research and advanced the science much faster than anyone imagined would happen. Just 10 years after the passage of Proposition 71, 10 projects (that) we have funded are in or have been in clinical trials including therapies for heart failure and HIV/AIDS and we anticipate several more in cancer, diabetes, sickle cell disease and blindness going into clinical trials this year. Its a record the people of California can be proud of.
CIRMs message, however, did not resonate at a meeting in January of the only state body charged with oversight of the enterprise the Citizens Financial Accountability Oversight Committee, which is chaired by state Controller John Chiang.
One member of the committee, Jim Lott, a hospital industry executive in the Los Angeles area and backer of Proposition 71, was sharply critical of a presentation by Thomas and Ellen Feigal, CIRMs senior vice president for research and development. According to the transcript of the meeting, Lott said, What can you tell me that weve done thats going to get my (13-year-old) daughter out of her wheelchair sooner (rather) than later after all this money has been spent?
See the original post:
State stem cell agencys at a crossroads - Business ...
- Global Stem Cell Reconstructive Market Detailed analysis of current Industry figures with forecasts growth by 2028 | Top Players; Osiris... - January 25th, 2021
- Cell Separation Technologies Market to Reach $28.76 Bn, Globally, by 2027 at 15.4% CAGR, Says Allied Market Research - PRNewswire - January 25th, 2021
- Stem Cell Therapy Market to Witness Increase in Revenues by 2025 NeighborWebSJ - NeighborWebSJ - January 25th, 2021
- Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada - BioSpace - January 23rd, 2021
- Comprehensive Report on Stem Cell Banking Market 2021 | Trends, Growth Demand, Opportunities & Forecast To 2027 |Cordlife, Cryo-Cell... - January 23rd, 2021
- Regenerative Medicine Market Size Worth $23.57 Bn By 2027; High demand for 3D bioprinting of tissues and organs to better understand their mechanism... - January 22nd, 2021
- BrainStorm Announces the Publication of Preclinical Data Highlighting the Potential of a NurOwn Derived Exosome-Based Treatment for COVID-19 ARDS -... - January 22nd, 2021
- Regenerative medicine is advancing health care in diverse ways - Hometown Focus - January 22nd, 2021
- Gene Pathway Linked to Development of Schizophrenia - Psychiatric Times - January 22nd, 2021
- Humanigen Announces the Addition of BARDA and Expansion of CRADA with the US Government to Develop Lenzilumab for COVID-19 - BioSpace - January 22nd, 2021
- Cell Sorting Market Size to Reach USD 805.1 Million By 2027 | Expanding Biotechnology And Pharmaceutical Industries will be the Major Factor Driving... - January 22nd, 2021
- BrainStorm's Covid-19 ARDS treatment improves lung function in study - Clinical Trials Arena - January 22nd, 2021
- Impact of Covid-19 on Automated Cell Culture Market Influencing the Industry Development and Forecast | BD, Tecan Trading, Sartorius, TAP Biosystems,... - January 22nd, 2021
- Global Live Cell Imaging Market Size is Expected to reach USD 3529.26 Million by 2025 and Registeri - PharmiWeb.com - January 22nd, 2021
- [Full text] Identification and Targeting of ThomsenFriedenreich and IL1RAP | OTT - Dove Medical Press - January 22nd, 2021
- New Genetic Disorder Discovered That Affects Brain and Craniofacial Skeleton - Technology Networks - January 22nd, 2021
- Parent Project Muscular Dystrophy Invests $1 Million in Satellos Bioscience to Support New Regenerative Medicine Technology - PRNewswire - January 22nd, 2021
- Stem cells on the ballot - Science Magazine - January 14th, 2021
- 2021 Startups to Watch: Ronawk's T-Blocks stack the future of stem cell research in an Olathe lab - Startland News - January 14th, 2021
- Towards a Cure: Carleton Research Team Working on Stem Cell Therapy to Reverse Type 1 Diabetes - Carleton Newsroom - January 14th, 2021
- Stem Cell Assay Market | Know the aspects that will serve as game-changers for the market - BioSpace - January 14th, 2021
- Center for cell and gene therapy to open next year - Harvard Gazette - January 14th, 2021
- Covid-19 Impact On Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020 Booming So Rapidly by 2027 | Fibrocell Science, Inc., Genzyme... - January 14th, 2021
- Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients... - January 14th, 2021
- PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33 - Business Wire - January 14th, 2021
- Global Research Antibodies and Reagents Market Report 2020-2027: Significant Opportunities from Emerging Asia-Pacific and Latin-American Markets -... - January 3rd, 2021
- Stem Cell Manufacturing Market Size 2020 Industry Analysis, Key Players, Growth Prospects, Revenue, Production, New Development, Business Share,... - January 3rd, 2021
- Stem Cell Cartilage Regeneration Market : Revenue, Growth, Business Outlook & Forecast 2020-2029 - PharmiWeb.com - January 3rd, 2021
- Global Tissue and Organ Transplantation Market to Surpass US$ 25.6 Billion by 2027, Says Coherent Market Insights (CMI) - Business Wire - January 3rd, 2021
- Viral Clearance Market Is Expected To Reach USD 724.5 Million By 2023 From An Estimated USD 271.2 Million In 2018, At A CAGR Of 21.7% - LionLowdown - December 28th, 2020
- Biobank Market Industry Network, Key Vendors, Growth Analysis, Size, Share, Revenue Strategies and Forecast Report 2020-2026 | Coherent Market... - December 28th, 2020
- Global Neural Stem Cells Market 2020-2026 updated Report with the latest scenarios based on the global COVID-19 Pandemic - Farming Sector - December 24th, 2020
- Organ and Tissue Transplantation and Alternatives - GlobeNewswire - December 24th, 2020
- Comprehensive Report on Animal Stem Cell Therapy Market 2021 | Size, Growth, Demand, Opportunities & Forecast To 2027 | ANIMAL CELL THERAPIES,... - December 22nd, 2020
- Canine Stem Cell Therapy Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026 - Factory Gate - December 22nd, 2020
- Adipose Tissue-Derived Stem Cells (ADSCS) Market Size Is Expected To Generate Huge Profits and Competitive Outlook - The Courier - December 22nd, 2020
- Webinar on benefits of 3D cell culture techniques - SelectScience - December 22nd, 2020
- Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients -... - December 22nd, 2020
- The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% - GlobeNewswire - December 22nd, 2020
- Orchard Therapeutics Receives EC Approval for Libmeldy for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) - GlobeNewswire - December 22nd, 2020
- Robert Gallo of the UM School of Medicine Institute of Human Virology and Global Virus Network Awarded Top Life Sciences and Medicine Prize from China... - December 22nd, 2020
- 3D Printing Industry review of the year: February 2020 - 3D Printing Industry - December 22nd, 2020
- Michigans Catholic bishops say 2 COVID-19 vaccines are OK morally but another is problematic - MLive.com - December 21st, 2020
- How Researchers Are Making Do in the Time of COVID-19 - The Wire Science - December 21st, 2020
- Stem cells in drug development - Nordic Life Science - December 19th, 2020
- Global Cell Culture Market by Product, Application, End-user and Region - Forecast to 2025 - PRNewswire - December 19th, 2020
- Glycostem and Ghent University sign license agreement on NK cell therapy technology | DNA RNA and Cells | News Channels - PipelineReview.com - December 19th, 2020
- EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan - BioSpace - December 19th, 2020
- Global Primary Antibodies Market To Reflect Impressive Growth Rate by 2028||Leading Players-Thermo F - PharmiWeb.com - December 19th, 2020
- US gets more help in raging battle against COVID-19 as FDA authorizes Moderna vaccine, the second allowed for emergency use - USA TODAY - December 19th, 2020
- Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes -... - December 19th, 2020
- Skandalaris LEAP winners announced | WashU Fuse | Washington University in St. Louis - Washington University in St. Louis Newsroom - December 19th, 2020
- Creative Medical Technology Holdings Announces Successful Application of ImmCelz Immunotherapy for Treatment of Stroke - PRNewswire - December 17th, 2020
- Glycostem and Ghent University sign license agreement on NK cell therapy technology - PRNewswire - December 17th, 2020
- Creative Medical Technology Stock Price Increased 80.77%: Why It Happened - Pulse 2.0 - December 17th, 2020
- CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire - December 14th, 2020
- EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan - Business Wire - December 14th, 2020
- 3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,... - December 14th, 2020
- Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress - GlobeNewswire - December 14th, 2020
- Researchers identify the origin of a deadly brain cancer - McGill Newsroom - December 14th, 2020
- Insights on the Global Stem Cell Therapy Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats - Technavio - Yahoo... - December 9th, 2020
- Better education needed to give patients improved understanding of gene therapies, new review highlights - University of Birmingham - December 9th, 2020
- Extended Virus Shedding After COVID in Some Patients With Cancer - Medscape - December 9th, 2020
- Global Cancer Stem Cells Market to Boost with CAGR of 11.8% and Cross a Margin of $1,898.3 Million During the Covid-19 Outbreak Exclusive Report [150... - December 9th, 2020
- City of Hope Doctors Present Innovative Therapies to Better Treat Blood Cancers at American Society of Hematology Virtual Conference - BioSpace - December 9th, 2020
- New DARZALEX (daratumumab) Data from GRIFFIN Study Show Deeper and Longer Responses in Patients with Newly Diagnosed Multiple Myeloma - PRNewswire - December 9th, 2020
- CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001 at American Society of Hematology Annual... - December 9th, 2020
- Genetic engineering transformed stem cells into working mini-livers that extended the life of mice with liver disease - Albany Times Union - December 9th, 2020
- Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis - PRNewswire - December 9th, 2020
- Stem cells: past, present, and future | Stem Cell Research ... - December 8th, 2020
- Jasper Therapeutics Announces Data from First Transplant-naive Patient in Phase 1 Clinical Trial of JSP191 as Conditioning Agent in Patients with SCID... - December 8th, 2020
- After boosting gene therapy focus, Bayer signs up to new cell therapy pact with Atara - FierceBiotech - December 8th, 2020
- Data published in Cancer Research show Secarna Pharmaceuticals' LNAplus(TM) ASOs targeting metadherin significantly slow progression and metastasis of... - December 8th, 2020
- Europe Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Material Type, Applications, and Country -... - December 8th, 2020
- Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology -... - December 8th, 2020
- Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020 - Business Wire - December 8th, 2020
- Incyte Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin... - December 8th, 2020
- Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company... - December 8th, 2020
- Meat-Tech Agrees to Acquire Cultured Fat Pioneer 'Peace of Meat' - PRNewswire - December 8th, 2020
- Actinium Reports 67 Percent Overall Response Rate in First Cohort in Actimab-A Venetoclax Combination Trial in Relapsed and Refractory AML at ASH -... - December 8th, 2020